| Q34354736 | Accelerated atheroma, antiphospholipid antibodies, and the antiphospholipid syndrome |
| Q26820245 | Accelerated atherosclerosis in patients with SLE--mechanisms and management |
| Q37143021 | Accelerated atherosclerosis is independent of feeding high fat diet in systemic lupus erythematosus-susceptible LDLr(-/-) mice |
| Q37709623 | Advances in immune-modulating therapies to treat atherosclerotic cardiovascular diseases |
| Q47689224 | Amygdalin ameliorates the progression of atherosclerosis in LDL receptor‑deficient mice |
| Q34981331 | Anti-inflammatory and immunomodulating properties of statins. An additional tool for the therapeutic approach of systemic autoimmune diseases? |
| Q37190468 | Antigen-induced immunomodulation in the pathogenesis of atherosclerosis. |
| Q34644504 | Antiinflammatory and immunomodulatory properties of statins |
| Q34005307 | Antiphospholipid antibodies and sub-clinical atherosclerosis in the Coronary Artery Risk Development in Young Adults (CARDIA) cohort |
| Q46165765 | Antiphospholipid antibodies from a patient with primary antiphospholipid syndrome enhance experimental atherosclerosis |
| Q34271982 | Antiphospholipid syndrome, antiphospholipid antibodies, and atherosclerosis |
| Q74068314 | Artherosclerosis as an infectious, inflammatory and autoimmune disease |
| Q28345191 | Atherosclerosis |
| Q35148621 | Atherosclerosis and antiphospholipid syndrome |
| Q37378106 | Atherosclerosis in autoimmune diseases |
| Q35538118 | CD4+ T cells in atherosclerosis |
| Q35557796 | Cardiovascular co-morbidity in patients with rheumatic diseases. |
| Q35747016 | Expression of interleukin-15 in mouse and human atherosclerotic lesions |
| Q34505818 | Extracellular heat shock protein 70 (HSPA1A) and classical vascular risk factors in a general population |
| Q37261617 | Immune mechanisms in atherosclerosis, especially in diabetes type 2 |
| Q37316712 | Immunogenic oxidized low-density lipoprotein/beta2-glycoprotein I complexes in the diagnostic management of atherosclerosis |
| Q35172183 | Immunomodulation for treatment and prevention of atherosclerosis |
| Q33770999 | Immunomodulation of vascular diseases: atherosclerosis and autoimmunity |
| Q34986341 | Innate and acquired immunity in atherogenesis |
| Q92369603 | Interleukin-17/Interleukin-21 and Interferon-γ producing T cells specific for β2 Glycoprotein I in atherosclerosis inflammation of systemic lupus erythematosus patients with antiphospholipid syndrome |
| Q36932166 | Is preclinical autoimmunity benign?: The case of cardiovascular disease |
| Q36577423 | Mechanisms of disease: atherosclerosis in autoimmune diseases |
| Q37209541 | Mechanisms of disease: the evolving role of regulatory T cells in atherosclerosis |
| Q78383751 | Oral tolerance with heat shock protein 65 attenuates Mycobacterium tuberculosis-induced and high-fat-diet-driven atherosclerotic lesions |
| Q43283992 | Prospective study on autoantibodies against apolipoprotein H (beta2GPI) in several clinical parameters from patients with terminal renal failure and functioning renal transplants |
| Q46227990 | Reduction of heat shock protein antibody levels by statin therapy |
| Q37027316 | Statin treatment for rheumatoid arthritis: a promising novel indication |
| Q36960925 | Systemic antiphospholipid syndrome and atherosclerosis |
| Q37033345 | Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention |
| Q39230390 | The immunology of atherosclerosis |
| Q35683321 | The role of endothelial cell reactive antibodies in peripheral vascular disease |
| Q41767127 | The western-type diet induces anti-HMGB1 autoimmunity in Apoe(-/-) mice. |
| Q37421814 | Translational mini-review series on immunology of vascular disease: accelerated atherosclerosis in vasculitis |
| Q82893705 | [Immunological aspects of atherosclerosis] |
| Q60961044 | β2-Glycoprotein I-Reactive T Cells in Autoimmune Disease |
| Q35126642 | β2-Glycoprotein I-specific T cells are associated with epitope spread to lupus-related autoantibodies |